Stock

Should I buy Moderna shares after strong Q4 results?

Moderna Inc. (NASDAQ: MRNA) shares advanced more than 15% after the company reported a quarterly report that blew away Wall Street analysts’ estimates.

The company’s management has authorized a new share repurchase program of $3 billion, and the fourth-quarter earnings results showed that Moderna is moving in the right direction.

The average selling price remained stable

Moderna reported strong fourth-quarter results this Thursday; total revenue has increased by 1162.7% Y/Y to $7.21 billion, $480 million above expectations, while the GAAP earnings per share were $11.29 (beats by $1.68).

Total product sales in the fourth quarter of 2021 were $6.9 billion compared to $4.8 billion in the third quarter. Moderna delivered  297 million doses to its customers during the fourth quarter, which represents an increase of more than 40% compared to the previous quarter.

Moderna recorded a net income of $4.9 billion in the fourth quarter compared to $3.3 billion in the third quarter, and the quarter-over-quarter improvement was driven by favorable manufacturing costs as the average selling price remained relatively stable.

The cost of sales was $952 million or 14% of the company’s product sales in the fourth quarter compared to $722 million or 15% of product sales in the third quarter.

The company’s results surpassed analysts’ consensus forecasts, and Moderna shares advanced more than 15% despite the fact that negative headlines out of Ukraine continue to dominate Wall Street.

Total revenue for the 2021 fiscal year reached $18.5 billion, while the GAAP net income was $12.2 billion. David Meline, CFO of Moderna, said:

The significant growth was driven by the sales of 807 million doses of the Company’s COVID-19 vaccine, resulting in product sales of $17.7 billion. The cost of sales was $2.6 billion, or 15% of the company’s product sales in 2021, including third-party royalties of $641 million.

Positive information is that Moderna announced a new booster candidate that combines an Omicron-specific vaccine with the firm’s standard COVID shot while the company’s management has authorized a new share repurchase program of $3 billion.

Technical analysis

Moderna shares advanced more than 15% after the company reported a strong quarterly report, and the current share price stands at $156.

Data source: tradingview.com

The important support levels are $140 and $120; $180 and $200 represent the current resistance levels. If the price jumps above $180, it will signal trading Moderna shares, and the next target could be around $200 resistance.

On the other side, if the price falls below $140 support, it would be a strong “sell” signal, and the next target could be around $120.

Summary

Moderna reported strong fourth-quarter results this Thursday, and the company’s management has authorized a new share repurchase program of $3 billion. The company’s results surpassed analysts’ consensus forecasts, and Moderna shares advanced more than 15% despite the fact that negative headlines out of Ukraine continue to dominate Wall Street.

The post Should I buy Moderna shares after strong Q4 results? appeared first on Invezz.

Disclaimer: MonopolyWinnersUpdates.com, its managers, its employees, and assigns (collectively "The Company") do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

Copyright © 2022 MonopolyWinnersUpdates.com. All Rights Reserved.

To Top